Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 116

Sort by

Sort Order Select

Journal Articles

Novel agents and immune invasion in Hodgkin lymphoma

Reid W. Merryman, Ann LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 243–248.

https://doi.org/10.1182/hematology.2019000029

Published: 2019

Journal Articles

Opportunities for immunotherapy in childhood acute myeloid leukemia

Adam J. Lamble, Sarah K. Tasian

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 218–225.

https://doi.org/10.1182/hematology.2019000357

Published: 2019

Journal Articles

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 252–259.

https://doi.org/10.1182/hematology.2019000030

Published: 2019

Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.

https://doi.org/10.1182/hematology.2019000032

Published: 2019

Journal Articles

Myeloma: next generation immunotherapy

Adam D. Cohen

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 266–272.

https://doi.org/10.1182/hematology.2019000068

Published: 2019

Journal Articles

CAR T-cell therapy: is it prime time in myeloma?

Surbhi Sidana, Nina Shah

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 260–265.

https://doi.org/10.1182/hematology.2019000370

Published: 2019

Journal Articles

Where does transplant fit in the age of targeted therapies?

Victor A. Chow, Ajay K. Gopal

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 287–293.

https://doi.org/10.1182/hematology.2019000033

Published: 2019

Journal Articles

Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?

Lori Muffly, Emily Curran

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 17–23.

https://doi.org/10.1182/hematology.2019000009

Published: 2019

Journal Articles

Microbiota modification in hematology: still at the bench or ready for the bedside?

Christopher J. Severyn, Ryan Brewster, Tessa M. Andermann

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 303–314.

https://doi.org/10.1182/hematology.2019000365

Published: 2019

Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.

https://doi.org/10.1182/hematology.2019000028

Published: 2019

Journal Articles

Moving immunotherapy into the front line in ALL

Amanda Winters, Lia Gore

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 209–217.

https://doi.org/10.1182/hematology.2019000017

Published: 2019

Journal Articles

Integrating patient-centered factors in the risk assessment of MDS

Rena J. Buckstein

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 373–380.

https://doi.org/10.1182/hematology.2019000041

Published: 2019

Journal Articles

Meeting the needs of CML patients in resource-poor countries

Hemant Malhotra, Jerald Radich, Pat Garcia-Gonzalez

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 433–442.

https://doi.org/10.1182/hematology.2019000050

Published: 2019

Journal Articles

Sequencing of therapies in relapsed follicular lymphoma

Loretta J. Nastoupil, Christopher R. Flowers, John P. Leonard

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 189–193.

https://doi.org/10.1182/asheducation-2018.1.189

Published: 2018

Journal Articles

Novel therapies for relapsed/refractory aggressive lymphomas

Jonathon B. Cohen

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 75–82.

https://doi.org/10.1182/asheducation-2018.1.75

Published: 2018

Journal Articles

Using genomics to define pediatric blood cancers and inform practice

Rachel E. Rau, Mignon L. Loh

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 286–300.

https://doi.org/10.1182/asheducation-2018.1.286

Published: 2018

Journal Articles

Antibody-based therapies in patients with acute lymphoblastic leukemia

Shira Dinner, Michaela Liedtke

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 9–15.

https://doi.org/10.1182/asheducation-2018.1.9

Published: 2018

Journal Articles

Novel immunotherapy approaches to follicular lymphoma

Christopher R. Flowers, John P. Leonard, Loretta J. Nastoupil

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 194–199.

https://doi.org/10.1182/asheducation-2018.1.194

Published: 2018

Journal Articles

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Michael A. Spinner, Ranjana H. Advani

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 200–206.

https://doi.org/10.1182/asheducation-2018.1.200

Published: 2018

Journal Articles

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Alison J. Moskowitz

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 207–212.

https://doi.org/10.1182/asheducation-2018.1.207

Published: 2018

NARROW

Novel agents and immune invasion in Hodgkin lymphoma

Opportunities for immunotherapy in childhood acute myeloid leukemia

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Indolent lymphomas: pushing the pace with novel agents

Myeloma: next generation immunotherapy

CAR T-cell therapy: is it prime time in myeloma?

Where does transplant fit in the age of targeted therapies?

Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?

Microbiota modification in hematology: still at the bench or ready for the bedside?

Management of older Hodgkin lymphoma patients

Moving immunotherapy into the front line in ALL

Integrating patient-centered factors in the risk assessment of MDS

Meeting the needs of CML patients in resource-poor countries

Sequencing of therapies in relapsed follicular lymphoma

Novel therapies for relapsed/refractory aggressive lymphomas

Using genomics to define pediatric blood cancers and inform practice

Antibody-based therapies in patients with acute lymphoblastic leukemia

Novel immunotherapy approaches to follicular lymphoma

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only